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Pericardial fluid proteomic label-free quantification
of differentially expressed proteins in ischemic
heart disease patients with systolic dysfunction by
nano-LC-ESI-MS/MS analysis†
Junaid Ullah,a Satwat Hashmi,b Arslan Ali, *c Faisal Khan,c Shahid Ahmed Sami,d
Nageeb Basir,e Syeda Saira Bokhari,e Hasanat Sharif,d Hesham R. El-Seedifg
and Syed Ghulam Musharraf *ac
Left ventricular systolic dysfunction (LVSD) is common in patients with pre-existing ischemic heart disease
(IHD) and myocardial infarction. An untargeted proteomic approach is used to improve the understanding
of the molecular mechanisms associated with LVSD and to find out potential proteomic signatures in
pericardial fluid. The pericardial fluid of IHD (n ¼ 45) patients was grouped into two categories according
to the left ventricular ejection fraction, LVEF $45 (n ¼ 33) and LVEF <45 (n ¼ 12), and analyzed by using
nano-liquid chromatography–mass spectrometry (nano-LC-MS/MS) technique. The nano-LC-MS/MS
analysis resulted in the identification of 709 pericardial fluid (PF) proteins in both normal and impaired
systolic functional groups (LVEF $45 vs. LVEF <45). Sixteen proteins were found to be differentially
expressed (p < 0.05, fold change >2) including 12 down-regulated and 4 up-regulated in the impaired
systolic functional group (LVEF <45) compared to the normal group (LVEF $45). Among the differentially
expressed proteins the inflammatory marker albumin, atherosclerosis marker apolipoprotein A-IV and
hedgehog-interacting protein marker of angiogenesis were predominantly associated with the impaired
LVEF <45 group. KEGG pathway analysis revealed that the hedgehog (Hh) signalling pathway is up-
regulated in LVSD reflecting the underlying molecular and pathophysiological processes.
Introduction
Cardiovascular disease (CVD) is one of the main causes of
mortality and disability worldwide. According to the World
Health Organization (WHO), in 2008 approximately 17.3 million
people died from cardiovascular disease and this will, expect-
edly, rise to 23.3 million annually by 2030.1 Ischemic heart
disease (IHD) is the most prevalent condition among the CVDs.
Le ventricular systolic dysfunction (LVSD) is common in
patients with IHD.2 LVSD refers to an impairment of the le
ventricular contractility that results in reduced le ventricular
ejection fraction (LVEF) and cardiac output. Patients with LVSD
were at increased risk of death compared to subjects with
a normal LVEF.3 A 10% reduction in LVEF predicts a 39%
increase in all-cause mortality, hospitalization and an increased
heart failure risk.4 Prevalence of LVSD increases substantially
with age and is more prevalent in men (7.6%) as compared to
women (2.6%)5
The measurement of proteins in biological samples plays
a key role in the diagnosis and prognosis of patients that are at
high risk of diseases. Pericardial uid has been used to
understand themolecular mechanism of disease in a number of
studies.6 Pericardial uid (PF) is an ultraltrate of the plasma
and a biochemical window into the heart by which information
related to the pathophysiological status of the heart can be
obtained.7 Pericardial uid is present between the two layers;
parietal and visceral of the pericardium and is produced by the
visceral pericardium of the heart. Under normal conditions, it
measures about 15–50 mL in volume. Many diseases including
ischemic heart disease, infections, and idiopathic causes can
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increase the volume and change its composition.8 The proteo-
mic analysis of pericardial uid may be an important tool to
nd out the pathophysiological mechanisms underlying cardiac
diseases and to nd out potential therapeutic targets.9 Several
proteomic signatures have been discovered and used in the
management of LVSD such as Brain Natriuretic Peptide (BNP),
which is released in the pericardial uid and serum by the
ventricles in response to increased wall tension or stretch of
cardiac chambers.10 The proteomic analysis of pericardial uid
in patients with lung bullae disease resulted in the identica-
tion of 1007 proteins which provided valuable insight into
disease mechanism.11 To the best of our knowledge, this is the
rst study constituting the proteomic proling of the pericar-
dial uid in patients with LVSD with established IHD.
The present study aimed to uncover the differentially
expressed proteins in the pericardial uid by a label-free
quantitative proteomic approach in IHD patients with
impaired (LVEF <45) and normal (LVEF $45) systolic function.
The study will help to improve the understanding of the
molecular mechanisms associated with LVSD and to nd out
potential proteomic signatures.
Material and methods
Experimental design and statistical analysis
For the present study fourty ve patients (43 men and 2 women)
were recruited with conrmed ischemic heart disease (IHD) at
South city and Aga Khan University Hospital Karachi, Pakistan.
A written informed consent was taken from each patient before
coronary artery bypass gra (CABG). In this study, patients with
renal insufficiency, metabolic bone diseases, valvular disease
moderate to severe, constrictive pericarditis and inltrative,
hypertrophic or restrictive cardiomyopathies, established
pulmonary disease and malignancy were excluded. Two-
dimensional and Doppler echocardiography was used for the
assessment of le ventricular systolic function following ASE
guideline 2009. Patients were further categorized into two
groups according to the LV ejection fraction: group A was 33
patients with normal le ventricular systolic function (LVEF
$45), and group B was 12 patients with impaired le ventricular
systolic function (LVEF <45) as depicted in Table 1. The study
was approved by the Ethical Review Board (ERB) of the Aga
Khan University Hospital and Institutional Review Board (IRB)
of International Centre for Chemical and Biological Sciences
(ICCBS), University of Karachi, Pakistan. All procedures fol-
lowed in this study were in accordance with the ethical princi-
ples of the 1964 declaration of Helsinki.
Sample collection and processing
Pericardial uid samples were collected from each subject in
pre-labeled clean and sterile falcon tubes. Samples were
centrifuged at 3500 rpm, for 15 min at 4 C to remove cellular
components. For further analysis aliquoted samples were
stored at 80 C in microcentrifuge tubes. Bicinchoninic acid
(BCA) procedure was followed for measurement of total protein
concentration according to the Kit protocol.12
FASP digestion
Each pericardial uid sample equivalent to 200 mg protein, were
digested using lter-aided sample preparation (FASP) method.13
In short, protein concentrates in 0.5 mL 10 kDa cutoff centri-
fuge lters were mixed with 500 mL of 6 M urea in 0.1 M tris/HCl
and the samples were centrifuged at 14 000g for 25 min at 20 C.
Aer centrifugation, 10 mL of 0.1 M Dithiotreitol (DTT) was
added to the lters, and incubated at 56 C for 30 min. Then, 10
mL of 0.3 M iodoacetamide (IAA) was added to the lters, aer
which the samples were incubated for 30 min in darkness.
Finally, 2 mg of trypsin (MS Grade, Thermo Scientic) in 50 mL of
100 mM NH4HCO3 was added to each lter. The protein to
enzyme ratio was 50 : 1. Samples were incubated overnight at
37 C and peptides were released and collected by centrifuga-
tion at 14 000g at 20 C for 25 min.
LC-MS/MS analysis
The protein digest were dissolved in 0.1% TFA and 1 mL
(equivalent to 2 mg) was injected on a C18-reverse-phase trap-
ping column (C18, Acclaim™ PepMap™ 100, 75 mm  2 cm,
particle size 3 mm, nanoViper, Thermo Fisher Scientic) and
was separated by C18-reverse-phase nano-LC column (75 mm 
15 cm Acclaim™ PepMap™ RSLC C18 column with 2 mm
particle size and 100 A pore size, NanoViper, Thermo Fisher
Scientic), using Nano-UHPLC, (Dionex, UltiMate 3000
RSLCnano System, Thermo Scientic, USA) coupled to MaXis II
ESI-QTOF Mass spectrometer (Bruker Daltonics, Bremen, Ger-
many). Buffers A and B contained 0.1% formic acid in ultra-pure
water and 0.1% formic acid in acetonitrile (ACN), respectively
were used for peptide elusion. ACN gradient at 300 nL min1
was used to separate peptides aer 6 min sample load at a ow
rate of 5 mL min1 with 2% B. Elution of the peptides were
achieved by applying a linear gradient of 1–35% B over 29 min,
with subsequent gradient increase to 95% B over 2 min, hold B
for 7 min at 95%, and then decreased to 2% B for 4min followed
by 12 min equilibration at 2% B. Data dependent acquisition
Table 1 Baseline characteristicsa
(LVEF $45%) (LVEF <45%)
N 33 12
Age [years; mean (SD)] 59.7  7.1 58.0  9.6





Creatinine [mg dL1; mean (SD)] 1.0  0.2 1.0  0.3
BUN [mg dL1; mean (SD)] 16.0  3.4 19.2  11.3
Echocardiographic parameters
LVEF [%; mean (SD)] 58.2  4.9 36.6  8
a SD standard deviation, BUN blood urea nitrogen, LVEF le ventricular
ejection fraction.



























































































(DDA) was carried out in positive ion mode. The parameters
were set as follows: end plate offset voltage was 500 V, capillary
voltage was 4500 V, dry gas ow rate was 4.0 L min1 and dry
temperature was 180 C. Scan mode for MS and MS/MS were
between 150 to 2200 m/z. The threshold for MS/MS was 2500
and cycle time of 3 s.
Label-free quantication
Bruker Daltonics Compass Data Analysis Soware (version 4.4)
was used to generate the molecular feature list for each LC-MS/
MS run. The resulting molecular features were transferred to
ProleAnalysis Soware to calculate buckets. A bucket is char-
acterized by its MH+ mass value, retention time, and intensity
values. The parameters for bucket calculation were set as,
retention time range 6–45 min, mass range 150–2200 m/z,
normalization with a quantile, value count of group attribute
within bucket were set as 2 and value count of bucket 30. Aer
bucket generation, peptide regulation ratios were calculated
using T-test and transferred to ProteinScape soware.
To link peptide regulation output with the identication
results, the LC-MS/MS raw data les of each run were converted
to (.xml) using Bruker Daltonics Compass Data Analysis So-
ware (version 4.4). The resulting xml les were imported to
ProteinScape soware for the Mascot Database search. Aer the
protein database search, peptide identication was linked to
their peptide regulation ratios by selecting the retention time
correction option and p-value <0.05 as assignment criteria.
Finally, protein regulation ratios were calculated from peptide
regulation ratios and a list of proteins includes quantication
information such as the number of peptides ratios, coefficient
of variation (CV) values, and the regulation ratios were
generated.14
MS/MS data analysis using ProteinScape
Nano-LC-MS/MS raw data les of each run were converted to
(.xml) and were searched using the Mascot search engine
(Version 2.6, Matrix Science, London, UK) triggered by Pro-
teinScape against Swiss-Prot database with the following
parameters: taxonomy lter was set to homo sapiens, for
proteolytic cleavages, trypsin was used with maximum missed
cleavages up to 1, oxidation of methionine as variable modi-
cations and carbamidomethyl of cysteine as xed modications
were allowed. Peptide mass tolerance was set at 0.08 Da and
fragment mass tolerance was set at 0.2 Da. Peptide charges were
set at +2, +3, and +4. The accepted FDR was set to <1%.
Bioinformatic analysis
Label-free quantied proteins were further subjected to bio-
informatic analysis, including gene ontology (GO) and KEGG
pathway analysis. The 16 differentially expressed proteins
sequence information was extracted from the online UniProt
knowledgebase database (https://www.uniprot.org/) and
retrieved in FASTA format. Functional classication of proteins
was done by gene ontology on the basis of biological process,
molecular process and cellular component using OmicsBox
(version 1.2, https://www.biobam.com/omicsbox/).15 HSP
Length cutoff 33 and expect value 1  103 were set as param-
eter for blastp-fast. Parameters for the gene ontology (GO)
annotations were set as; Hit lter 500, GO weight 5, HSP-Hit
coverage cutoff 0, annotation cutoff 55 and E-value-hit-lter 1
 106. The level 2 pie/bar chart conguration was used for
showing annotated sequences in GO graphs. The association
between differentially expressed quantied proteins with each
other and their interaction with other proteins were assessed by
the STRING EMBL soware (version 11.0, https://string-db.org/
). The medium condence score of 0.400 was used.16
Results
For the present study, workow is shown in Fig. 1. The data
acquisition stage consisted of pericardial uid sample analysis
through nano-LC-ESI-MS/MS by using the data dependent
acquisition (DDA) strategy. The statistical analysis stage was
used to nd out signicantly differentially expressed proteins in
both groups (LVEF $45 vs. LVEF <45) followed by the bio-
informatics analysis (GO and KEGG) to understand the biolog-
ical role of these proteins.
Label-free proteomics and identication of differentially
expressed proteins
A total of 709 pericardial uid proteins were identied using the
DDA strategy in both groups (LVEF $45 vs. LVEF <45) (Table
S1†). The annotated spectra of all the identied proteins along
with the differentially expressed proteins are given in the ESI
le.† For a better look, the double fold change for the log 2-
based values derived from the quotient (LVEF <45/LVEF $45) is
presented in Fig. 2 as a volcano plot, statistically determined by
a P-value <0.05, at 2.0-fold change. The identied proteins in the
two groups of the experiment (LVEF $45/LVEF <45) were
analyzed and compared, 16 proteins were found differentially
expressed, including 12 down-regulated and 4 up-regulated
proteins in impaired (LVEF <45) systolic function group as
Fig. 1 Workflow of the present study. First stage is the data acquisition
stage; it consisted of pericardial fluid (PF) sample preparation and its
nano-LC MS/MS analysis using DDA strategy. The second stage is the
data analysis stage; it consisted of statistical analysis and bioinformatic
analysis (GO and KEGG pathway analysis).



























































































compared to normal (LVEF$45) systolic function group. Serum
albumin, mesothelin, E3 ubiquitin-protein ligase SH3RF3, Rho
GTPase-activating protein 44 and serotransferrin were the most
down-regulated while AT-rich interactive domain-containing
protein 4A, zinc nger protein GLI2, zinc nger protein 831,
and hedgehog-interacting protein were the most up-regulated
proteins. The results with protein name, accession number,
isoelectric point, sequence coverage, molecular weight, fold-
change and t-test p-values are presented in Table 2.
Functional classication of differentially expressed proteins
A GO classication was performed for the 16 signicant differ-
entially expressed proteins in patients with normal (LVEF $45)
and impaired (LVEF <45) systolic function group as shown in
the pie chart at graph level 2 (Fig. 3 and Table S2†). The GO
analysis of differentially expressed protein revealed involvement
in multiple biological processes in both groups. The highest
proportion of (18%, 7 proteins: MTUS1, TRFE, PHF1, MSLN,
SH3R3, OSBL6, RHG44) sequences were found to be involved in
cellular processes followed by biological regulation (15%, 6
proteins: MTUS1, TRFE, PHF1, SH3R3, OSBL6, RHG44), and
metabolic processes (13%, 5 proteins: PHF1, MSLN, SH3R3,
OSBL6, APOA4), while the remaining functions such as
response to a stimulus; localization, signaling, developmental
process, cellular component organization, locomotion, immune
system process biological adhesion and multicellular organ-
ismal process, were observed in less proportions in both groups
(LVEF $45/LVEF <45). Differentially expressed, proteins were
also classied based on their molecular functions, such as
protein involved with binding (81%, 13 proteins: MTUS1, PHF1,
MSLN, EFC4B, GLI2, RHG44, TRFE, SRBP2, ARI4A, SH3R3,
Fig. 2 Volcano plot of peptide areas, derived from the quotient (LVEF
<45/LVEF$45) with log 2 fold-change (x-axis) versus log 10 p-value
(y-axis). The orange dots, located in the upper-left and upper-right
sections, corresponding to high fold changes and low p-values, indi-
cate significantly regulated signals while the gray dots indicate the
non-significant differentially expressed signals. For the differentially
expressed signals, a p-value of <0.05 and fold change of >2 are set as
the significant thresholds.
Table 2 Differentially expressed proteins identified in ischemic heart disease patients with normal LV systolic function (LVEF$45) and impaired
















ALBU_HUMAN Serum albumin 69.3 5.9 3565.8 62 73.9 42.24 5.02 0.0029 Down
TRFE_HUMAN Serotransferrin 77.0 6.8 2660.8 43 50.9 44.56 2.09 0.0006 Down
APOA4_HUMAN Apolipoprotein A-IV 45.4 5.3 461.2 12 32.6 44.87 1.86 0.0029 Down
MSLN_HUMAN Mesothelin 68.9 6.0 76.2 3 5.4 572.57 4.60 0.0001 Down
RHG44_HUMAN Rho GTPase-activating protein
44
89.2 6.1 51.1 2 1.1 12.74 2.26 0.0007 Down
OSBL6_HUMAN Oxysterol-binding protein-
related protein 6
106.2 6.5 38.4 2 2.1 36.23 1.89 0.0001 Down
GLI2_HUMAN Zinc nger protein GLI2 167.7 6.9 37.7 2 1.5 664.68 4.47 0.005 Up
SRBP2_HUMAN Sterol regulatory element-
binding protein 2
123.6 8.7 34.2 1 1.0 1.51 1.50 0.0147 Down
PHF1_HUMAN PHD nger protein 1 62.1 9.3 31.2 1 1.4 6.49 1.42 0.0001 Down
ZN831_HUMAN Zinc nger protein 831 177.8 8.7 25.7 1 1.0 5.91 4.03 0.0009 Up
EFC4B_HUMAN EF-hand calcium-binding
domain-containing protein 4B
45.6 4.9 20.2 1 2.5 16.97 1.50 0.0147 Down
NU205_HUMAN Nuclear pore complex protein
Nup205
227.8 5.8 20.0 1 0.4 922.75 1.08 0.0116 Down
MTUS1_HUMAN Microtubule-associated tumor
suppressor 1
141.3 7.3 19.6 1 0.8 8.45 1.50 0.0147 Down
HHIP_HUMAN Hedgehog-interacting protein 78.8 8.2 17.6 1 2.0 6.71 2.34 0.0184 Up
SH3R3_HUMAN E3 ubiquitin-protein ligase
SH3RF3
92.7 9.1 17.0 1 1.0 10.22 3.17 0.0001 Down
ARI4A_HUMAN AT-rich interactive domain-
containing protein 4A
142.7 5.0 15.6 1 1.0 3.54 4.49 0.0042 Up



























































































OSBL6, APOA4, ZN831), transporter activity (12%, 2 proteins:
TRFE, OSBL6) and catalytic activity (6%, 1 protein: HHIP).
OmicsBox analysis, also classied the differentially
expressed proteins according to their cellular component. Most
of the proteins were assigned to the organelle (12%, 4 proteins
MTUS1, MSLN, NU205, OSBL6), followed by extracellular region
(12%, 4 proteins: TRFE, MSLN, APOA4, ALBU) and membrane
(9%, 3 proteins: MTUS1, MSLN, OSBL6), while the remaining
component such as extracellular region part, membrane part,
membrane-enclosed lumen, supramolecular complex and
protein-containing complex were observed in fewer
proportions.
KEGG pathway analysis
STRING was used to gain an insight into the interactive links
known to be associated with the 16 proteins expressed differ-
entially in the dataset. Interactive links between the differen-
tially regulated proteins could be traced as shown in Fig. 4. A
total of 8 RCTM/KEGG pathways were observed in the present
study. The suggested pathways of these differentially regulated
proteins are listed in Table 3, along with term ID, term deni-
tion, observed gene count, background gene count, FDR and
matching proteins within a network.
Fig. 3 Go annotation of “biological process” “molecular function” and “cellular component” analyze by OmicxBox (version 1.2, https://
www.biobam.com/omicsbox/).
Fig. 4 Interactive network analysis and association of 16 differentially
expressed pericardial fluid proteins obtained from STRING (version
11.0, https://string-db.org/).




























































































Proteomics is used to perform quantitative as well as qualitative
analyses of a large array of proteins in biological samples.17
Recently, label-free quantitative proteomics (LFQP) has gained
more popularity as mass spectrometer's efficiency has signi-
cantly improved. The LFQP becomes a widely applied approach
for identifying as well as quantifying differentially expressed
proteins. It increases the dynamic range of proteins 3 to 4 time
as compared to 2DE and is more sensitive and rapid than many
other proteomic methods.18
In the present study, we have found 16 signicantly differ-
entially expressed proteins in LVEF $45 vs. LVEF <45. Among
the differentially expressed proteins 12 proteins down-regulated
in impaired (LVEF <45) systolic function group, including
serum albumin, serotransferrin, apolipoprotein A-IV, meso-
thelin, Rho GTPase-activating protein 44, sterol regulatory
element-binding protein 2, oxysterol-binding protein-related
protein 6, PHD nger protein 1, nuclear pore complex protein
Nup205, EF-hand calcium-binding domain-containing protein
4B, Microtubule-associated tumor suppressor 1, and E3
ubiquitin-protein ligase SH3RF3. While, the remaining 4
proteins were found up-regulated in impaired (LVEF <45)
systolic function group including, zinc nger protein 831, zinc
nger protein GLI2, AT-rich interactive domain-containing
protein 4A and hedgehog-interacting protein. One of the
down-regulated protein in patients with impaired (LVEF <45)
group is albumin. Albumin is a 66.5 kDa protein which is the
most abundant protein in plasma. Albumin plays a signicant
role in regulating plasma oncotic pressure and uid distribu-
tion throughout the body compartment.19 Serum albumin's
physiological properties include anti-inammatory, antioxi-
dant, anticoagulant activity and regulating the transport of
cholesterol.20 Normal pericardial uid contains between one
quarter and one third of the protein of plasma and demon-
strates a far higher proportion of albumin to other proteins in
the pericardial uid.21,22 Hypoalbuminemia, with serum
albumin levels less than 3.5 g dL1 (ref. 23) has been linked to
several cardiovascular diseases such as coronary artery disease,
congenital heart disease, stroke and heart failure.24 Hypo-
albuminemia has been reported in one-third of heart failure
patients with reduced ejection fraction (LVEF <45).25 In
concordance with the ndings in the serum, the present nd-
ings suggest that the down-regulation of albumin in the peri-
cardial uid is associated with impaired systolic function of the
le ventricle. Hence, it could be used as a potential risk marker
in identifying the patients with le ventricular systolic
dysfunction.
Another down-regulated protein in impaired (LVEF <45)
group is serotransferrin. It is an iron binding protein, respon-
sible for transporting iron from sites of heme degradation and
absorption to those of utilization and storage.26 The serum level
of serotransferrin decreases in inammatory conditions such as
diabetes mellitus which in turn increases the risk of CVD.27 It
has been demonstrated that decrease level of plasma sero-
transferrin is associated with rheumatic valvular heart disease
(RVD),28 and coronary artery dilation (CAD) caused by Kawasaki
disease.29 The down-regulation of serotransferrin in impaired
(LVEF <45) group may be due to the inammatory response of
the body as its level also decreases in patients with CKD and
ESRD.30
Apo A-IV is another protein that is down-regulated in
impaired (LVEF <45) group. Apo A-IV, is an oligosaccharide
containing protein with a molecular weight of 46 kDa.31 Its
concentration in plasma is 15–37 mg dL1.32 Apo A-IV is
synthesized in the intestine and is incorporated into the
chylomicrons and secreted into the intestinal lymph during fat
absorption.33 Apo A-IV plays a signicant role in the lipid and
glucose metabolism.34 It also acts as anti-inammatory agent
and potentially exert its anti-atherogenic effect35 by reverse
cholesterol pathway, which removes cholesterol from periph-
eral cells and transports it to the liver.36 Clinical studies have
demonstrated an inverse relationship between apo A-IV and
coronary artery diseases.37 Apo A-IV deciency is associated with
atherosclerosis, cardiovascular diseases, chronic pancreatitis,
malabsorption disorders38 and diabetes mellitus.39 Low Apo A-
Table 3 Pathways of differentially expressed protein identified in ischemic heart disease patients with normal LV systolic function (LVEF$45) and
impaired LV systolic function (LVEF <45)
KEGG/RCTM pathways







HSA04340 Hedgehog signaling pathway 2 46 0.009 GLI2, HHIP
HSA05217 Basal cell carcinoma 2 63 0.009 GLI2, HHIP
HSA-381426 Regulation of insulin-like growth factor
(IGF) transport and uptake by insulin-like
growth factor binding proteins (IGFBPs)
3 123 0.012 ALB, MSLN, TF
HSA-8957275 Post-translational protein
phosphorylation
3 106 0.012 ALB, MSLN, TF
HSA-8957322 Metabolism of steroids 3 146 0.012 ALB, OSBPL6, SREBF2
HSA-8963899 Plasma lipoprotein remodeling 2 30 0.012 ALB, APOA4
HSA-194068 Bile acid and bile salt metabolism 2 42 0.0157 ALB, OSBPL6
HSA-5632684 Hedgehog ‘on’ state 2 82 0.0405 GLI2, HHIP



























































































IV levels in these patients with systolic dysfunction as compared
to patients with preserved EF may point towards a disease
mechanism underlying the progression from preserved EF to
reduced EF.
Among the up-regulated differentially expressed proteins in
patients with impaired (LVEF <45) group is AT-rich interactive
domain containing protein 4A. It is also known as ARID4A or
retinoblastoma – binding protein 1 is encoded by the gene
ARID4A.40 Studies shows that ARID4A play a signicant role in
various types of cancer such as breast cancer and leukemia.
ARID4A binds with other proteins and play a key role in cell
proliferation and differentiation.41 Zinc nger protein 831
belongs to a large class of zinc nger proteins (ZNFs) is up-
regulated in impaired (LVEF <45) group. Zinc nger proteins
(ZNFs) have a key role in tissue development and differentia-
tion. Alterations in ZNFs are involved in the development of
several diseases such as congenital heart disease, defects of the
cardiac outow tract and diabetes.42
KEGG network analysis with pathway enrichment identied
that the hedgehog signaling pathway is up-regulated in
impaired (LVEF <45) group as compared to the normal (LVEF
$45) group. Network analysis revealed that two up-regulated
proteins zinc nger protein GLI2 and hedgehog-interacting
protein are involved in hedgehog signaling (Hh) pathway. Hh
signaling pathway was rst identied as a key mediator of
organogenesis in invertebrates by Nusslein–Volhard and Wie-
schaus in 1980.43 Three Hh homologues have been discovered
in mammals in the early 1990s, including Indian hedgehog
(Ihh), Sonic (Shh) and Desert (Dhh). Sonic is one of the best
studied and most widely expressed during embryonic develop-
ment as compared to Dhh and Ihh.44 Hh signaling pathway is
known to regulate cell differentiation and migration during
embryonic development but in post-natal life, the Hh signaling
can be recapitulated under several pathological conditions,
including cardiac ischemia.45 The absence of tissue specic Hh
signalling components reduces proangiogenic gene expression
and thus loss of coronary vasculature that leads to car-
diomyocyte cell death and ventricular failure. The presence of
the Hh signalling pathway may protect and limit the extent of
myocardial ischemic damage.46 Many theories are postulated to
elucidate the regulation mechanism of Hh signaling pathway in
ischemic heart tissues. It has been shown that the expression of
hypoxia-induced factor-1 (HIF-1) and inammation in cardiac
ischemia, activate the Hh signaling pathway, resulting in
elevated expression of angiogenic and proangiogenic factors to
facilitate angiogenesis and neovascularization in ischemic
tissues.47 In concordance with the previous ndings, our results
also validate the recapitulation of Hh signaling pathway in
ischemic heart disease patients but more prominently in
impaired (LVEF <45) group.48 Considering that the Hh signaling
pathway is essential for the formation of new coronary vessels,
this nding signals an important adaptive mechanism in
humans with LVSD.49
KEGG pathway analysis also showed that pathways involved
in the Metabolism of steroids (pathway proteins: albumin,
oxysterol-binding protein-related protein 6, sterol regulatory
element-binding protein 2), plasma lipoprotein remodelling
(pathway proteins: albumin, apolipoprotein A-IV) and bile acid
and bile salt metabolic pathways (pathway proteins: albumin,
oxysterol-binding protein-related protein 6) were down-
regulated in impaired (LVEF <45) group as compared to the
normal (LVEF $45) group.
Conclusion
In conclusion, sixteen proteins were found to be differentially
expressed between IHD patients with LVEF <45 and LVEF $45.
Among the differentially expressed proteins the inammatory
marker albumin, atherosclerosis marker apolipoprotein A-IV
and hedgehog-interacting protein marker of angiogenesis
were predominantly associated with impaired LVEF <45 group.
The KEGG pathway analysis revealed that the hedgehog
signaling pathway is up regulated in impaired LVEF <45 group.
These ndings suggest important associations of heart systolic
function with specic proteins reecting its underlying patho-
physiological mechanisms, however, they need to be further
validated in a larger number of samples.
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